Global Health Investment Corporation, an investment company, and LTS Lohmann, a pharmaceutical technology company, led a $17m Series A round in Mircron Biomedical, a biotechnology company, with participation from GRA Venture Fund and J2 Ventures. “Micron’s technology has the potential to change the way we administer many of today’s currently injected drugs and vaccines. We are deeply committed to bringing Micron’s MAP technology-based drug and vaccine products to market, improving access and having a positive impact on patients globally. This financing, and in particular our new investors, will help us to achieve our goals,” Steven Damon, Micron CEO.